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Background
Malignant lymphomas (ML) are increasingly important
causes of morbidity and mortality in sub-Saharan Africa
including Tanzania, possibly due to HIV and AIDS. How-
ever, the biological characterization ML including their
HIV and Epstein-Barr virus (EBV) association as well as
DLBCL subtypes in Tanzania is still sketchy. This prevents
diagnostic/prognostic comparison as well as application of
established therapeutic protocols.
Materials and methods
Selected archival, diagnostic ML biopsies (N=60) collected at
Muhimbili National Hospital (MNH), Dar es Salaam, Tanza-
nia, between 1996 and 2006 and their corresponding clini-
cal/histopathological notes werea n a l y z e db yh i s t o p a t h o l o g y ;
immunohistochemistry (IHC) using CD20, CD3, CD30,
CD10, MUM1p, BCL-6, BCL-2, and Ki-67 cell markers;
flow-cytometry (FC) for DNA ploidy; and in situ hybridiza-
tion (ISH) (n=25) for EBV-encoded RNA (EBER). Available
sera (N=35) were screened by ELISA for HIV antibodies.
Results
Out of the evaluated cases, 27 were diffuse large B-cell
lymphoma (DLBCL) of which a slight majority (55.6%,
n=15/27) had activated B cell-like (ABC) and 44.4%
(12/27) had germinal center B cell-like (GCB) immuno-
phenotype, although this was not statistically significant
(p-value 0.547, Chi
2 Test). Overall, 40% (24/60) ML were
aneuploid mostly (63.0%, 17/27) the DLBCL and T-cell
lymphoma (TCL) [54.5%, 6/11] which differences were not
statistically significant (p-value 0.06, Chi
2 Test. DNA index
(DI) of FC-analyzed ML ranged from 1.103 to 2.407
(median=1.51) and most (75.0%) aneuploid cases showed
high (>40%) cell proliferation by Ki-67 reactivity (p-value
0.031, statistically significant, Fisher’s Exact Test). The
majority (51.4%, 19/37) of EBER ISH analyzed lymphoma
biopsies were positive (p-value 0.87, not statistically signifi-
cant, Chi
2 Test). Of the serologically tested lymphomas
40.0% (14/35) were HIV positive, mostly with high
(≥40.0%) Ki-67 reactivity [p-value=0.05, statistically signifi-
cant, Pearson Correlation].
Conclusions
Lymphomas at MNH appear to have frequent aneuploidy
and EBER positivity as well as high DNA indices and
tumor proliferation (Ki-67). DLBCL phenotype heterogene-
ity was similar to that observed in other countries suggest-
ing applicability of established intervention approaches.
HIV was apparently associated with high lymphoma cell
proliferation but extended studies are needed to clarify this.
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